Skip to main content

08-10-2020 | Diabetes | News | Article

News in brief

More real-world evidence for SGLT2 inhibitor cardioprotection

Author: Eleanor McDermid

medwireNews: Further real-world evidence demonstrates the positive cardiovascular effects of sodium-glucose cotransporter (SGLT)2 inhibitors in people with type 2 diabetes, in this case when compared against dipeptidyl peptidase (DPP)-4 inhibitors.

During an average 0.9 years of follow-up, the risk for the primary composite endpoint of myocardial infarction, ischemic stroke, or cardiovascular death was reduced by a significant adjusted 24%, with SGLT2 inhibitors versus DPP-4 inhibitors. This was driven by a 40% reduction in the risk for cardiovascular death; there was also a significant 18% reduction in myocardial infarction risk and a nonsignificant 15% reduction in the risk for stroke.

In addition, there was a significant 57% reduction in the risk for heart failure, report Kristian Filion (McGill University, Montreal, Quebec, Canada) and co-researchers in The BMJ.

“Similar results were observed for canagliflozin, dapagliflozin, and empagliflozin and across patient subgroups defined by age, sex, past insulin use, and history of cardiovascular disease or history of heart failure,” they note.

For this analysis, the team drew data from the Canadian Network for Observational Drug Effect Studies (CNODES), matching 209,867 new users of SGLT2 inhibitors with an equal number of existing users of DPP-4 inhibitors.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group

BMJ 2020; 370: m3342

See the research in context now

with trial summaries, expert opinion and congress coverage